Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome.
Saved in:
| Title: | Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome. |
|---|---|
| Authors: | Premji R; Montage Medical Group, Monterey, California, USA., Nylen ES; Department of Endocrinology, VAMC and George Washington University School of Medicine, Washington, District of Columbia, USA., Naser N; Department of Endocrinology, VAMC and George Washington University School of Medicine, Washington, District of Columbia, USA., Gandhi S; Department of Endocrinology, VAMC and George Washington University School of Medicine, Washington, District of Columbia, USA., Burman KD; Department of Endocrinology, Georgetown University School of Medicine, Washington Hospital Center, Washington, District of Columbia, USA., Sen S; Department of Endocrinology, VAMC and George Washington University School of Medicine, Washington, District of Columbia, USA. |
| Source: | Metabolic syndrome and related disorders [Metab Syndr Relat Disord] 2022 Aug; Vol. 20 (6), pp. 321-328. Date of Electronic Publication: 2022 Apr 22. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101150318 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-8518 (Electronic) Linking ISSN: 15404196 NLM ISO Abbreviation: Metab Syndr Relat Disord Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1557-8518 |
|---|---|
| DOI: | 10.1089/met.2022.0004 |
